Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2006-06-29
2009-08-11
Chernyshev, Olga N. (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S141100, C424S158100, C424S009100, C530S387100, C530S388100, C530S389100
Reexamination Certificate
active
07572446
ABSTRACT:
There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
REFERENCES:
patent: 5594114 (1997-01-01), Goodearl et al.
patent: 6303321 (2001-10-01), Tracey et al.
patent: 6323329 (2001-11-01), Bullerdiek
patent: 6448223 (2002-09-01), Tracey et al.
patent: 6468533 (2002-10-01), Tracey et al.
patent: 7097838 (2006-08-01), Tracey et al.
patent: 2002/0009749 (2002-01-01), Ozaki et al.
patent: 2003/0113323 (2003-06-01), Tracey et al.
patent: 2003/0143194 (2003-07-01), Tracey et al.
patent: 2004/0120953 (2004-06-01), Tracey et al.
patent: 1 079 849 (2002-01-01), None
patent: 362166897 (1986-01-01), None
patent: WO 96/25493 (1996-08-01), None
patent: WO 97/23611 (1997-07-01), None
patent: WO 99/59609 (1999-11-01), None
patent: WO 02/074337 (2002-09-01), None
patent: WO 02/092004 (2002-11-01), None
patent: WO 2004/004763 (2004-01-01), None
patent: WO 2008076758 (2008-06-01), None
Levy et al., Intensive Care Medicine, 29(4): 530-538, Mar. 2003.
Straino et al., Journal of Investigative Dermatology, (e-pub) 2008).
Bianchi et al., Immunological Reviews, 220(1): 35-46, Dec. 2007.
(abstract only) Czura et al. Advances in Immunology, 84: 181-200, 2004.
Ozaki, S., “High Mobility Group Protein HMG1/HMG2: Clinical Significance of the Autoantibodies,”Jpn. J. Clin. Immun., 21(3)95-107 (1998).
Zhang, M. et al., “Tumor Necrosis Factor,” inThe Cytokine Handbook, (Academic Press Limited), Third Edition, pp. 517-547 (1998).
Johns, E. W., et al. “History, Definitions and Problems,” inThe HMG Chromsomal Problems, (Academic Press), London: Chapter 1, pp. 1-7 (1982).
Landsman, D., et al., “A Signature for the HMG-1 Box DNA-Binding Proteins”,BioEssays, 15(8): 539-546 (1993).
Baxevanis, A.D., et al., “The HMG-1 Box Protein Family: Classification and Functional Relationships,”Nucleic Acids Res., 23(9):1604-1613 (1995).
Merenmies, J., et al., “30-kDa Heparin-Binding Protein of Brain(Amphoterin) Involved in Neurite Outgrowth,”J. Biol. Chem., 266(25): 16722-16729 (1991).
Milev, P., et al., “High Affinity Binding and Overlapping Localization of Neurocan and Phosphacan/Protein-Tyrosine Phosphatase—ζ/β with Tenascine -4, Amphoterine, and the Heparin-Binding Growth-Associated Molecule,”J. Biol. Chem., 273(12):6998-7005 (1998).
Salmivirta, M., et al., “Neurite Growth-Promotion Protein (Amphoterin, p. 30) Binds Syndecan,”Exp. Cell Res., 200:444-451 (1992).
Melloni, E., et al., “Identity in Molecular Structure Between “Differentiation Enhancing Factor” of Murine Erithroleukemia Cells and the 30 kD Heparin-Binding Protein of Developing Rat Brain,”Biochemical and Biophysical Research Communications, 210(1): (1995).
Melloni, E., et al., “Extracellular Release of the ‘Differentiation Enhancing Factor’, and a HMG1 Protein Type, is an Early Step in mUrine Erythroluekemia Cell Differentiation,”FEBS Lett., 368: 466-470 (1995).
Mohan, P.S., et al., “Sulfoglycolipids Bind to Adhesive Protein Amphoterin (p30) in the Nervous System,”Biochemical and Biophysical Research Communications, 182(2) (1992).
Yamawaki, M., et al., “Generation and Characterization of Anti-Sulfoglucuronosyl Paragloboside Monoclonal Antibody NGR20 and its Immunoreactivity with Peripheral Nerve,”J. Neurosci. Res., 44: 586-593 (1996).
Vassalli, J., et al., “The Plasminogen Activator/Plasmin System,”J. Clin. Invest., 88: 1067-1072 (1991).
Parkkinen, J., et al., “Interactions of Plasminogen and Tissue Plasminogen Activator (t-PA) with Amphoterin,”J. Biol. Chem., 266(25): 16730-16735 (1991).
Redlitz, A., et al., “Receptors for Plasminogen and t-PA: An Update,”Baillière's Clinical Haemtology, 8(2): 313-327 (1995).
Sobajima, J., et al., “Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in ulcerative colitia: non-histone chromosomal proteins, HMG1 and HMG2,”Clin. Exp. Immunol., 107:135-140 (1997).
Sobajima, J., et al., “Anti-neutrophil cytopasmic antibodies (ANCA) in ulcerative colitis: anti-cathepsin G and a novel antibody correlate with a refractory type,”Clin. Exp. Immunol., 105:120-124 (1996).
Sporatore, B., et al., “Extracellular high-mobility group 1 protein is essential for murine erythroleukaemia cell differentiation,”Biochem. J., 320:253-256 (1996).
Tomita, N., et al., “Direct in Vivo Gene Introduction into Rat Kidney,”Biochemical and Biophysical Research Communications, 186(1): 129-134 (1992).
Wang, H., et al., “HMG-1 as a Late Mediator of Endotoxin Lethality in Mice,”Science, 285:248-251 (1999).
Falciola, L., et al., “High Mobility Group 1 Protein is Not Stably Associated with the Chromosomes of Somatic Cells,”J. Cell Biol., 137 (1):19-26 (1997).
Vanderbilt, J.N., et al., “Monoclonal Antibodies as Probes for the Complexity, Phylogeny, and Chromatin Distribution of High Mobility Group Chromosomal Proteins 1 and 2,”J. Biol. Chem., 260(16):9336-9345 (1985).
Bustin, M., et al., “Antigenic Determinants of High Mobility Group Chromosomal Proteins 1 and 2,”Biochem., 21:6773-6777 (1982).
Tsuneoka, M., et al., “Monoclonal Antibody Against Non-Histone Chromosomal Protein High Mobility Group 1 Co-Migrates With High Mobility Group 1 Into the Nucleus,”J. Biol. Chem., 261(4):1829-1834 (1986).
Bianchi, M.E., et al., “The DNA Binding Site of HMG1 Protein is Composed of Two Similar Segments (HMG Boxes), Both of Which Have Counterparts in Other Eukaryotic Regulatory Proteins,”EMBO J. 11(3):1055-1063 (1992).
Abraham, E., et al., “Cutting Edge: HMG-1 as a Mediator of Acute Lung Inflammation,”J. Immunol., 165:2950-2954 (2000).
Andersson, U., et al., “High Mobility Group 1 Protein (HMG-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes,”J. Exp. Med., 192:565-570 (2000).
Bustin, M. “Revised Nomenclature for High Mobility Group (HMG) Chromosomal Proteins,”Trends Biochem. Sci., 26:152-153 (2001).
Degryse, B., et al., “The High Mobility Group (HMG) Boxes of the Nuclear Protein HMG1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells,”J. Cell Biol., 152:1197-1206 (2001).
Wang, H., et al., “Proinflammatory Cytokines (Tumor Necrosis Factor and Interleukin 1) Stimulate Release of High Mobility Group Protein-1 by Pituicytes,”Surgery, 126:389-392(1999).
Passalacqua, M., et al., “Stimulated Astrocytes Release High-Mobility Group 1 Protein, an Inducer of Lan-5 Neuroblastoma Cell Differentiation,”Neuroscience, 82(4):1021-1028 (1998).
Chou, D. K. H., et al., “Identity of Nuclear High-Mobility-Group Protein, HMG-1, and Sulfoglucuronyl Carbohydrate-Binding Protein, SBP-1, in Brain,”J. Neurochem., 77:120-130 (2001).
Imamura, T., et al., “Interaction with p53 Enhances Binding of Cisplatin-Modified DNA by High Mobility Group 1 Protein,”J. Biol. Chem., 276(10):7534-7540 (2001).
Ise, T., et al., “Transription Factor Y-Box Binding Protein 1 Binds Preferentially to Cisplatin-Modified DNA and Interacts With Proliferating Cell Nuclear Antigen,”Cancer Res., 59:342-346 (1999).
Jung, F., et al., “Antibodies Against a Peptide Sequence Located in the Linker Region of the HMG-1/2 Box Domains in
Tracey Kevin J.
Wang Haichao
Chernyshev Olga N.
Hamilton Brook Smith & Reynolds PC
Macfarlane Stacey
The Feinstein Institute for Medical Research
LandOfFree
Antagonists of HMG1 for treating inflammatory conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists of HMG1 for treating inflammatory conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of HMG1 for treating inflammatory conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4125854